Literature DB >> 36273040

Intraoperative subconjunctival steroid reduces the incidence of pseudophakic macular oedema: a cohort study of 20,066 consecutive phacoemulsification surgeries.

Michelle Ai Ling Teo1, Edward Bloch2, Ramu Muniraju3, Paul Ursell3.   

Abstract

BACKGROUND/
OBJECTIVES: Pseudophakic macular oedema remains the most common sight-threatening complication following cataract surgery. This study aims to assess the effect of intraoperative subconjunctival steroids on the rate of pseudophakic cystoid macular oedema.
METHODS: A retrospective, observational database study of 20 066 consecutive phacoemulsification surgeries. The incidence of pseudophakic cystoid macular oedema was compared in eyes that did and did not receive intraoperative subconjunctival steroid injection during routine cataract surgery.
RESULTS: Intraoperative subconjunctival injection of dexamethasone or betamethasone sodium phosphate significantly reduced the odds of developing pseudophakic cystoid macular oedema across the cohort (odds ratio: 0.67; 95% confidence interval: 0.46-0.98, p = 0.039). The effect of subconjunctival steroids on pseudophakic macular oedema remained independently associated on multivariate logistic regression analysis (p = 0.028).
CONCLUSION: This study demonstrates that administration of intraoperative subconjunctival steroid injection is associated with a reduced incidence of pseudophakic cystoid macular oedema in routine, uncomplicated cataract surgery.
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Entities:  

Year:  2022        PMID: 36273040     DOI: 10.1038/s41433-022-02290-1

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   4.456


  1 in total

1.  Severe corneal melting after cataract surgery in patients prescribed topical postoperative NSAIDs and dexamethasone/neomycin combination therapy.

Authors:  Emily Cabourne; Nicola Lau; Declan Flanagan; Julie Nott; Jill Bloom; Romesh Angunawela
Journal:  J Cataract Refract Surg       Date:  2020-01       Impact factor: 3.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.